Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Ben on +44 1494 818005 or Ben@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Ben Chadwick
Team Leader
Ben@zenopa.com
+44 1494 818005

Testimonials
Zenopa helps their candidates in a very professional way in order to further develop their careers. With Zenopa helping me in every step of the recruitment process and in providing guidance in answeri...
William, 2012

AstraZeneca commits to new malaria drug initiative

28 June 2010 00:00 in Pharmaceutical Company Product News


AstraZeneca is to ally with an international not-for-profit organisation in a collaboration designed to find new treatments for malaria.

The agreement will see the pharmaceutical company provide the Medicines for Malaria Venture with access to its compound library in order to identify potentially promising drugs.

This process will involve the screening of around 500,000 compounds for treatments which demonstrate effectiveness against the lethal malaria parasite P. falciparum, with the initiative intended to form the basis of new anti-malarial drug discovery projects.

It is hoped that schemes such as this will eventually lead to the creation of a one-dose cure for malaria, a disease which is becoming increasingly dangerous due to the development of drug-resistant strains.

David Brennan, AstraZeneca's chief executive officer, said: "Our experience with infection research, and indeed with all of our research and development efforts, has taught us that we will only find solutions to today's global health challenges through collaborative efforts."

Last week, AstraZeneca announced the commencement of a new clinical trial programme designed to support the safety and efficacy profile of the new depressive disorder treatment TC-5124.

Other news stories from 28/06/2010

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd